ArticleBMC infectious diseases2026
Factors associated with interferon-gamma release assay positivity in patients with psoriasis: a cross-sectional study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe interferon-gamma release assay (IGRA) is recommended for latent tuberculosis infection (LTBI) screening prior to biologic therapy in psoriasis. Yet factors influencing IGRA positivity in this population remain insufficiently characterized.
objectivesThis study aimed to identify clinical factors associated with IGRA positivity among patients with psoriasis and to develop an internally validated model to summarize these associations in routine dermatological care.
methodsWe retrospectively analysed 1,126 patients with psoriasis without a documented history of prior tuberculosis (285 IGRA-positive and 841 IGRA-negative) at a single dermatology centre. Variables associated with IGRA positivity in univariable analysis were entered into a multivariable logistic regression model, which was internally validated using bootstrap resampling.
resultsThe overall IGRA positivity rate was 25.3%. IGRA positivity increased markedly with age, from 8.2% in patients aged ≤ 30 years to 45.6% in those aged > 60 years, with an optimal ROC-derived cutoff of 49 years (sensitivity, 0.561; specificity, 0.762). In multivariable analysis, older age (OR 1.048, 95% CI 1.037-1.059, p < 0.001), pulmonary nodules (OR 1.608, 95% CI 1.094-2.365, p = 0.016), and higher eosinophil percentage (OR 1.109, 95% CI 1.033-1.190, p = 0.004) were independently associated with increased odds of IGRA positivity, whereas prior biologic exposure was associated with reduced odds (OR 0.705, 95% CI 0.512-0.969, p = 0.031). The eight-variable multivariable model demonstrated acceptable discrimination (AUC 0.726; optimism-corrected AUC 0.717, 95% CI 0.690-0.763) and good calibration (Brier score 0.167). Decision curve analysis suggested net clinical benefit across a threshold range of approximately 5%-50%.
conclusionsOlder age, pulmonary nodules, and higher eosinophil percentage were independently associated with IGRA positivity, while prior biologic exposure showed an inverse association likely related to selection bias. The model showed acceptable internal performance and may provide supplementary context, but should not replace standard pre-biologic tuberculosis assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.